Pharmaceuticals Interventions for Smoking Cessation Programs
/ 0
- Details
- Category: Vol. 83, December 2015
- Hits: 89
Pharmaceuticals Interventions for Smoking Cessation Programs
Abstract
Aims: Smoking cessation remains a global health priority, with significant efforts directed towards developing effective pharmacotherapies and behavioral interventions. Methodology: This review examines current and emerg-ing therapies for smoking cessation, focusing on their efficacy, safety profiles, and potential implications for clinical practice. Results: Established first-line treatments include nicotine replacement therapies (NRT), bupropion, and varenicline, sup-ported by robust evidence from randomized controlled trials (RCTs). Second-line options, such as nortriptyline and cloni-dine, may be considered for individuals unable to tolerate first-line medications. Emerging therapies, like cytisine, show prom-ise but require further investigation. Conversely, naltrexone’s efficacy for other dependencies does not extend to smoking ces-sation based on current evidence. Topiramate, with its complex pharmacological profile, presents a novel avenue for explora-tion, particularly for individuals concerned about weight gain. Conclusion: Individualized treatment plans tailored to pa-tient preferences and medical history are crucial for optimizing smoking cessation outcomes. Continued research and the de-velopment of innovative therapies hold promise for reducing the global burden of tobacco-related diseases.